📰 Poster Presentation News
Page 2 - Poster Presentation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Poster Presentation. Real-time updates on events, politics, business and more.
February 27, 2024
– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received...
February 7, 2024
/PRNewswire/ -- The "High Potent Medicines Conference" conference has been added to ResearchAndMarkets.coms offering. Looking and the current market scenario,...
December 12, 2023
At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimensResponses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% v...
December 12, 2023
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...
December 11, 2023
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...
December 11, 2023
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...
December 11, 2023
SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in patients with refractory chronic...